Read more
This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.
List of contents
Targeted therapies in gliomas: An overview.- Targeting chemotherapy resistance in glioblastoma through modulation of ABC transporters.- Resistance of Glioblastomas to Radiation Therapy.- The blood-brain barrier in glioblastoma multiforme: Pathology and therapeutic implications.- Resistance of brain tumours to small-molecule targeted therapies: lessons from various cancer types.- Drug repurposing to circumvent chemotherapy resistance in brain tumours.- Small molecule inhibitors in glioblastoma: Key pathways and resistance mechanisms.- Imaging Targeted Therapy Response and Resistance in Glioblastoma.- Drug Resistance in Malignant Meningiomas.- Recurrence of Low-Grade Glioma - Have the Targeted Therapies Improved for Better Outcomes?.- Host-Tumor Interactions in Brain Cancer Metastasis Leading to Drug Resistance.
About the author
Amanda Tivnan, PhD, is Senior Postdoctoral Research Fellow, Department of Physiology and Medical Physics, The Royal College of Surgeons, Dublin, Ireland.
Summary
This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.
Additional text
“This is a complete monograph on the molecular and cell biology of 'brain tumors' resistant mechanisms. The book discusses chemotherapy and radiotherapy of brain malignancies including gliomas, ependynomas, and meningiomas. … I highly recommend this book as a reference and research tool for neurosurgeons, oncologists, neurologists, residents, and students.” (Joseph Grenier, Amazon.de, May, 2018)
Report
"This is a complete monograph on the molecular and cell biology of 'brain tumors' resistant mechanisms. The book discusses chemotherapy and radiotherapy of brain malignancies including gliomas, ependynomas, and meningiomas. ... I highly recommend this book as a reference and research tool for neurosurgeons, oncologists, neurologists, residents, and students." (Joseph Grenier, Amazon.de, May, 2018)
